Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.
Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.
The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.
In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.
Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.
Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.
Viridian Therapeutics (NASDAQ: VRDN) announced Phase 1/2 clinical trial updates for its lead product candidate, VRDN-001, targeting Thyroid Eye Disease (TED). Interim results show robust IGF-1 response with no significant adverse effects, suggesting the potential for lower dosing. The company ended Q1 2022 with $175 million in cash, expected to fund operations into 2024. R&D expenses increased to $17.7 million, contributing to a net loss of $25.7 million. The VRDN-002 trial is on track for top-line data in Q3 2022, aiming to enhance treatment convenience for TED patients.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced it will report financial results for Q1 2022, ending March 31, after market close on May 12, 2022. A conference call will take place at 4:30 p.m. ET on the same day, accessible via phone or webcast. The company's focus is on developing treatments for serious diseases, with lead candidate VRDN-001 targeting insulin-like growth factor-1 receptor for thyroid eye disease, and VRDN-002, an extended half-life anti-IGF-1R antibody for convenient subcutaneous administration.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will participate in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, starting at 4:30 p.m. ET. The conference will feature a corporate overview presentation. A live webcast and replay are available on Viridian's investor relations website.
Viridian focuses on innovative treatments for serious diseases, with its leading candidate, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease. The second candidate, VRDN-002, is designed for convenient subcutaneous administration.
Viridian Therapeutics (NASDAQ: VRDN) has secured a debt financing agreement with Hercules Capital for up to $75 million. The initial drawdown of $5 million has been completed, with additional funds contingent on milestones and lender approval. As of December 31, 2021, Viridian reported a cash position exceeding $197 million, expected to fund operations through 2024, excluding this new facility. The financing aims to enhance the company's operational flexibility while advancing clinical programs VRDN-001 and VRDN-002, targeting thyroid eye disease.
Viridian Therapeutics has initiated a Phase 1 clinical trial for VRDN-002, a monoclonal antibody designed to treat thyroid eye disease (TED). This trial involves 16 healthy volunteers receiving ascending doses of VRDN-002 to assess its safety and efficacy as a low-volume subcutaneous injection. Results are anticipated mid-year. This milestone supports Viridian's strategy to enhance patient care for TED, potentially allowing for at-home self-administration or treatment in a physician's office.
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm focused on treating serious diseases, will have its CEO, Jonathan Violin, participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 10:40 a.m. ET. This event highlights the company's efforts to advance new therapies, particularly VRDN-001, a monoclonal antibody for thyroid eye disease, and VRDN-002, a half-life extended treatment option. Interested parties can view the live webcast and replay on Viridian's website.
Viridian Therapeutics (NASDAQ: VRDN) reported financial results for Q4 and FY 2021, highlighting a strong cash position of $197 million to fund operations into 2024.
The company has two ongoing clinical trials for its IGF-1R antibodies, VRDN-001 and VRDN-002, targeting Thyroid Eye Disease (TED), with top-line data expected in Q2 and mid-2022, respectively.
Despite a net loss of $28.9 million in Q4 2021, this is an improvement from $90.7 million in the previous year, driven by reduced R&D expenses.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will report its financial results for the fourth quarter and full year ended December 31, 2021, on March 10, 2022, after market close. The management will host a conference call at 4:30 p.m. ET on the same day. Interested parties can listen by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international) with conference ID: 13727096. The call will also be available via live webcast on the company's investor site. Viridian focuses on developing treatments for serious diseases, targeting insulin-like growth factor-1 receptor for thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20 PM ET. The event aims to discuss advancements in treatments for serious diseases, focusing on their lead product, VRDN-001, targeting thyroid eye disease (TED). This condition can cause severe complications, necessitating surgical interventions. A live webcast and replay of the chat will be available on Viridian's website.
Viridian Therapeutics has received FDA clearance for its investigational new drug application for VRDN-002, a novel monoclonal antibody using half-life extension technology. The VRDN-002 is designed for low-volume subcutaneous injection to treat thyroid eye disease (TED). The company plans to initiate a first-in-human Phase 1 clinical trial to assess safety and pharmacokinetics, with results expected in mid-2022. This marks a key developmental milestone as Viridian aims to enhance treatment convenience for TED patients.
FAQ
What is the current stock price of Viridian Therapeutics (VRDN)?
What is the market cap of Viridian Therapeutics (VRDN)?
What does Viridian Therapeutics, Inc. do?
What is VRDN-001?
What condition does Viridian Therapeutics aim to treat?
How does VRDN-001 work?
Who are Viridian Therapeutics' partners?
What is the financial condition of Viridian Therapeutics?
Why is thyroid eye disease a focus for Viridian Therapeutics?
How can I stay updated on Viridian Therapeutics' progress?
Where is Viridian Therapeutics listed?